Skip to content
DataLookout
Menu

NCT07760246

A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Primary completion date: Dec 16, 2026 to Dec 30, 2026
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
  2. Notable Recruitment opened
    • Start date changed from estimate of Aug 17, 2026 to Aug 20, 2026
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

QT-interval corrected for heart rate, e.g. using the method of Fridericia change from baseline (ΔQTcF), paired with the verducatib plasma concentrations
Timeframe: Up to day 31

Secondary (1)

QT-interval corrected for heart rate, e.g. using the method of Fridericia change from baseline (ΔQTcF), paired with the moxifloxacin plasma concentrations

Arms and interventions

Moxifloxacin placebo followed by Verducatib followed by Moxifloxacin placeboExperimental
Moxifloxacin followed by Verducatib placebo followed by Moxifloxacin placeboExperimental
Moxifloxacin placebo followed by Verducatib placebo followed by MoxifloxacinExperimental

Drugs: Verducatib, Moxifloxacin, Placebo resembling Verducatib, Placebo resembling Moxifloxacin

Sites

1 site in 1 country

  • CRS Clinical Research Services Mannheim GmbHMannheim, Germany